Last reviewed 2026-04-23 · How we verify

1PC111

This drug is a small molecule that targets the PI3K/AKT pathway.

This drug is a small molecule that targets the PI3K/AKT pathway. Used for Advanced solid tumors with PI3K/AKT pathway alterations.

At a glance

Mechanism of action

It works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This inhibition leads to a decrease in AKT activity, resulting in anti-tumor effects.

Approved indications

• Advanced solid tumors with PI3K/AKT pathway alterations

Common side effects

• Hyperglycemia
• Diarrhea
• Nausea
• Vomiting
• Fatigue

Key clinical trials

• Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.